Comparative Pharmacology
Head-to-head clinical analysis: HARMONYL versus RAUWILOID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HARMONYL versus RAUWILOID.
HARMONYL vs RAUWILOID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Harmonyl is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, leading to decreased peripheral vascular resistance and blood pressure.
Rauwiloid (alseroxylon) is a rauwolfia alkaloid that depletes catecholamines and serotonin from postganglionic sympathetic nerve endings and the central nervous system by inhibiting vesicular monoamine transporter (VMAT). This leads to reduced peripheral vascular resistance and decreased sympathetic outflow, resulting in antihypertensive and antipsychotic effects.
25 mg orally once daily, taken with food. Maximum dose: 50 mg once daily.
2 mg orally twice daily, adjusted based on response; maximum 4 mg twice daily.
None Documented
None Documented
Terminal half-life: 12–18 hours (mean 15 h); extends to 24–30 h in hepatic impairment
Terminal elimination half-life is approximately 10–12 hours. Clinical context: Requires twice-daily dosing for sustained antihypertensive effect; steady-state achieved in 2–3 days.
Renal: 70% as unchanged drug; Biliary/fecal: 20% as metabolites; 10% other
Primarily renal excretion of metabolites; ~60–80% of a dose is eliminated in urine as metabolites, with <1% as unchanged drug. Biliary/fecal excretion accounts for ~15%.
Category C
Category C
Antihypertensive
Antihypertensive